<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308131">
  <stage>Registered</stage>
  <submitdate>29/06/2009</submitdate>
  <approvaldate>6/07/2009</approvaldate>
  <actrnumber>ACTRN12609000541202</actrnumber>
  <trial_identification>
    <studytitle>The Utility of Plasma Free Cortisol in the Assessment of Adrenal Function in Patients with Pituitary Disease</studytitle>
    <scientifictitle>The Utility of Plasma Free Cortisol in the Assessment of Adrenal Function in Patients with Pituitary Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adrenal function</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 250 mcg synacthen test (250 mcg synacthen administered intramuscularly (IM) with cortisol measurements before and 30 and 60 minutes after synacthen) and a 1 mcg synacthen test (1 mcg synacthen administered intravenously (IV) with cortisol measurements before and 30 and 60 minutes after synacthen). These tests will be performed once each to each subject separated by approximately 7 days. The tests will be performed in healthy subjects (to define a normal reference range) and in subjects with pituitary disease previously defined as either adrenocorticotrophic hormone (ACTH) sufficient or deficient by current gold standard tests.</interventions>
    <comparator>The 1mcg and 250 mcg synacthen tests will be performed once each in each subject about 7 days apart. Measurements of total and free cortisol in pituitary subjects by mass spectrometry will be compared to total cortisol by immunoassay. The normal subjects will be used to define the reference range for cortisol by mass spectrometry. The definition of pituitary subjects as either ACTH sufficient or deficient will be historical and based on the assessment of the hypothalamic/pituitary/adrenal (HPA) axis after pituitary surgery.</comparator>
    <control>Historical</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sensitivity of basal and synacthen-stimulated free cortisol (by mass spectrometry) to diagnose adrenal insufficiency. The normal subjects will be used to define the reference range for cortisol by mass spectrometry. The definition of pituitary subjects as either ACTH sufficient or deficient will be historical and based on the assessment of the HPA axis after pituitary surgery using current gold standard assessments (e.g insulin tolerance test or unequivocally normal or abnormal morning cortisol).</outcome>
      <timepoint>At time of study (cross-sectional study)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sensitivity of basal and synacthen-stimulated total cortisol (by mass spectrometry) to diagnose adrenal insufficiency. The normal subjects will be used to define the reference range for cortisol by mass spectrometry. The definition of pituitary subjects as either ACTH sufficient or deficient will be historical and based on the assessment of the HPA axis after pituitary surgery using current gold standard assessments (e.g insulin tolerance test or unequivocally normal or abnormal morning cortisol).</outcome>
      <timepoint>At time of study (cross-sectional study)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pituitary patients: Clearly diagnosed with either ACTH sufficiency/deficiency

Normal volunteers: Age 20-80 yrs</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Pregnancy, advanced malignancy, active infection, liver failure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate>13/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>29/11/2010</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Department of Health, South Australia</primarysponsorname>
    <primarysponsoraddress>Citi Centre Building
11 Hindmarsh Square
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>Bedford Park SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>St Vincent's Hospital</othercollaboratorname>
      <othercollaboratoraddress>41 Victoria Parade
Fitzroy Victoria 3065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to determine whether measurement of total and free cortisol by mass spectrometry improves the diagnostic accuracy of synacthen tests to assess adrenal function in patients with pituitary disease.</summary>
    <trialwebsite />
    <publication>Burt MG, Mangelsdorf BL, Rogers A, Ho JT, Lewis JG, Inder WJ, Doogue MP. Free and total plasma cortisol measured by immunoassay and mass spectrometry following ACTH1?24 stimulation in the assessment of pituitary patients. J Clin Endocrinol Metab 2013;98:1883-90</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Repatriation General Hospital</ethicname>
      <ethicaddress>Daws Rd
Daw Park SA 5041</ethicaddress>
      <ethicapprovaldate>14/02/2008</ethicapprovaldate>
      <hrec>87/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Dr Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park SA 5041</address>
      <phone>+61 8 82751094</phone>
      <fax />
      <email>morton.burt@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Dr Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park SA 5041</address>
      <phone>+61 8 82751094</phone>
      <fax />
      <email>morton.burt@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park SA 5041</address>
      <phone>+61 8 82751094</phone>
      <fax />
      <email>morton.burt@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd, Daw Park SA041</address>
      <phone>61882751094</phone>
      <fax />
      <email>morton.burt@sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>